

1 Impaired Neutralizing Antibody Response to COVID-19 mRNA Vaccines in Cancer Patients

2
3 #Cong Zeng^{1,2}, #John P. Evans^{1,2,3}, #Sarah Reisinger⁴, Jennifer Woyach⁵, Christina Liscynesky⁶, Zeinab El
4 Boghdadly⁶, Mark P. Rubinstein⁷, Karthik Chakravarthy⁷, Linda Saif^{8,9,10}, Eugene M. Oltz¹¹,
5 Richard J. Gumina¹², *Peter G. Shields⁴, *Zihai Li⁷, and *Shan-Lu Liu^{1,2,10,11}

6
7 ¹ Center for Retrovirus Research, The Ohio State University, Columbus, OH 43210, USA

8 ² Department of Veterinary Biosciences, The Ohio State University, Columbus,
9 OH 43210, USA

10 ³ Molecular, Cellular and Developmental Biology Program,
11 The Ohio State University, Columbus, OH 43210, USA

12 ⁴ Comprehensive Cancer Center, James Cancer Hospital, The Ohio State University,
13 Columbus, OH 43210, USA

14 ⁵ Division of Hematology, James Comprehensive Cancer Center, The Ohio State University,
15 Columbus, OH 43210, USA

16 ⁶ Internal Medicine, Division of Infectious Diseases, Department of Internal Medicine,
17 The Ohio State University, Columbus, OH 43210, USA

18 ⁷ Division of Medical Oncology, Department of Internal Medicine, Pelotonia Institute for Immuno-Oncology,
19 The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA

20 ⁸ Center for Food Animal Health, Animal Sciences Department, OARDC,
21 College of Food, Agricultural and Environmental Sciences, Wooster, OH 44691, USA

22 ⁹ Veterinary Preventive Medicine Department, College of Veterinary Medicine,
23 The Ohio State University, Wooster, OH 44691, USA

24 ¹⁰ Viruses and Emerging Pathogens Program, Infectious Diseases Institute,
25 The Ohio State University, Columbus, OH 43210, USA

26 ¹¹ Department of Microbial Infection and Immunity, The Ohio State University,
27 Columbus, OH 43210, USA

28 ¹² Department of Medicine, The Ohio State University, Columbus, OH 43210, USA

29
30
31 *Corresponding Authors:

32 Liu.6244@osu.edu

33 Zihai.Li@osumc.edu

34 Peter.Shields@osumc.edu

35
36 # Authors contributed equally to this letter.

37 **Abstract:**

38 There is currently a critical need to determine the efficacy of SARS-CoV-2 vaccination for
39 immunocompromised patients. In this study, we determined the neutralizing antibody response in 160
40 cancer patients diagnosed with chronic lymphocytic leukemia (CLL), lung cancer, breast cancer, and
41 various non-Hodgkin's lymphomas (NHL), after they received two doses of mRNA vaccines. Serum from
42 46 mRNA vaccinated health care workers (HCWs) served as healthy controls. We discovered that (1) cancer
43 patients exhibited reduced neutralizing antibody titer (NT₅₀) compared to HCWs; (2) CLL and NHL patients
44 exhibited the lowest NT₅₀ levels, with 50-60% of them below the detection limit; (3) mean NT₅₀ levels in
45 patients with CLL and NHL was ~2.6 fold lower than those with solid tumors; and (4) cancer patients who
46 received anti-B cell therapy exhibited significantly reduced NT₅₀ levels. Our results demonstrate an urgent
47 need for novel immunization strategies for cancer patients against SARS-CoV-2, particularly those with
48 hematological cancers and those on anti-B cell therapies.

49
50 **Main:**

51 In response to the global public health crisis caused by the COVID-19 pandemic, several SARS-CoV-2
52 vaccines were rapidly developed including the Pfizer/BioNTech BNT162b2 and Moderna mRNA-1273
53 mRNA vaccines. However, clinical trials of these mRNA vaccines did not investigate their efficacy in
54 vulnerable populations, including immunocompromised patients. With rising vaccination rates and an
55 easing of public health measures, there is a critical need to determine the efficacy of SARS-CoV-2
56 vaccination for such patients, who may experience a reduced efficacy of administered vaccines¹. It has
57 already been demonstrated that organ transplant recipients, who are under immunosuppressive therapy to
58 prevent rejection, exhibit reduced responsiveness to SARS-CoV-2 vaccination^{2,3}. Cancer patients represent
59 another critical population of immunocompromised individuals who, due to the nature of the disease or to
60 treatment with immunomodulatory therapies, may not exhibit a robust response to mRNA vaccination. A
61 better understanding of the factors governing response to vaccination in cancer patients is critical to inform
62 clinical decisions about the need for booster doses, the timing of vaccine administration, the need to

63 interrupt treatment courses for vaccination, and general guidance about the level of protection achieved by
64 vaccination in cancer patients. To this end, this study examines the neutralizing antibody response to
65 Pfizer/BioNTech BNT162b2 and Moderna mRNA-1273 vaccination in a cohort of patients with solid tumor
66 and hematological malignancies.

67 The study population included 160 cancer patients (54 chronic lymphocytic leukemia (CLL), 45 non-
68 Hodgkin's lymphoma (NHL), 29 lung cancer, 30 breast cancer, and 2 breast cancer with CLL) recruited
69 through medical record screening for vaccine appointments or recent post-vaccine administration, as well as
70 an independent cohort of 46 health care workers (HCWs), who have no history of cancer. Cancer patients
71 had a median age of 66 years while the median age of HCWs were 38 years. No cancer patient or HCW was
72 COVID-19 positive as confirmed by nucleocapsid-based ELISA. About 61% of cancer patients (n=98) and
73 52% of the HCWs (n=24) received BNT162b2, compared to 39% (n=62) and 48% (N=22) who received the
74 mRNA-1273, respectively. We collected serum samples for 159/160 cancer patients between 31 and 232
75 days (median 134 days) post-second dose, and HCW serum samples were obtained at 6 months post-second
76 dose. Cancer diagnoses and treatments of the patients are shown in **Table 1**. The largest treatment groups
77 were 47 patients with B-cell malignancies (28 CLL and 19 NHL) who received B cell depletion therapy or
78 other B cell-suppressing drugs (such as anti-CD20 monoclonal antibodies and Bruton tyrosine kinase (BTK)
79 inhibitors) during the study period; and 46% (n=28) of solid tumor patients received immune checkpoint
80 inhibitors against PD-1 or PD-L1.

81 We assessed sera for neutralizing antibody titers using a secreted *Gaussia*-luciferase SARS-CoV-2-
82 pseudotyped-lentivirus-based virus neutralization assay as previously described⁴. Briefly, pseudotyped virus
83 was incubated with serial dilutions of patient sera and used to infect HEK293T-ACE2 cells (BEI NR-52511).
84 Infected cells then secreted *Gaussia*-luciferase into the culture media which was harvested 48hrs and 72hrs
85 after infection, and luminescence was measured by a BioTek Cytation5 plate-reader. The resulting
86 luciferase output was used to calculate a neutralization titer at 50% efficiency of maximal inhibition (NT₅₀).
87 To ensure valid comparisons, the serum samples of all cancer patients and HCWs were processed side-by-
88 side in the same experiment.

89 We first compared the neutralizing antibody titers of cancer patients with those of HCWs. Overall,
90 cancer patients exhibited reduced neutralizing antibody responses, with a mean NT₅₀ of 220 compared to a
91 mean NT₅₀ of 522 for HCWs (**Fig. 1a**); this is despite the relatively shorter median time (134 days) after the
92 second dose of vaccination for cancer patients as compared to HCW, which is an average of ~180 days.
93 Patients with CLL exhibited the lowest neutralizing antibody response, with over 61% (n=34) of patients
94 exhibiting undetectable NT₅₀ values (below 40), compared to 49%, 31%, and 28% for NHL (n=22), lung
95 cancer (n=9), and breast cancer patients (n=9), respectively (**Fig. 1b**). The mean NT₅₀ of patients with CLL
96 and NHL (158 and 127, respectively) was ~2.6 fold lower than that of solid tumor patients (369) (**Fig. 1a**).
97 This is consistent with reports that SARS-CoV-2 infection induced weak humoral immune responses in
98 patients with hematological cancers⁵. Interestingly, there were a few CLL patients that exhibited high titer
99 while none were observed for the NHL patients (**Fig. 1b**).

100 Given the common usage of B-cell depleting therapies in the treatment of hematological cancers⁶⁻⁸ and
101 their likelihood of impacting vaccine efficacy, we then examined the effect of anti-B-cell therapy on
102 neutralizing antibody response. The treatment included anti-CD20 antibodies Obinutuzumab and Rituximab,
103 as well as BTK inhibitors Ibrutinib, Zanubrutinib, Pirtobrutinib, and Acalabrutinib. Notably, we found that
104 CLL and NHL patients who received anti-B cell therapy exhibited 2.7-fold (p = 0.0483) and 3.1-fold (p =
105 0.0030) reduced neutralizing antibody response to mRNA vaccine compared to those without anti-B cell
106 therapy, respectively (**Fig. 1c**).

107 The programmed death-1 (PD-1) receptor is an important immune checkpoint molecule that promotes
108 exhaustion/dysfunction in chronically activated T-cells⁹. Disruption of PD-1 or its ligand PD-L1 is a
109 common treatment to rejuvenate T cell function in cancer patients^{10,11}. Given this role, we examined how
110 anti-PD-1/PD-L1 treatments might modulate the host immune response to mRNA vaccination. However, we
111 did not find significant differences in NT₅₀ or development of immune-related adverse events between anti-
112 PD-1/PD-L1 antibody treated and un-treated lung/breast cancer patients (**Fig. 1d**).

113 Other factors potentially impacting immune stimulation were also assessed, including age and gender of
114 patients, types of vaccine received and time of sample collection. Moderna mRNA-1273 outperformed

Pfizer BNT162b2 vaccine in mean NT₅₀ by 2.8-fold for HCWs ($p = 0.0053$) and 2.1-fold for cancer patients ($p = 0.0044$) (**Fig. 1e**). This is consistent with our previous findings that Moderna mRNA-1273 vaccinated individuals exhibit higher NT₅₀ levels compared to Pfizer BNT162b2¹². Given previous findings that neutralizing antibody response to mRNA vaccination is age dependent¹³, we also examined the possible correlation between age and NT₅₀ titer. However, no significant correlation between age and NT₅₀ values was observed in these cancer patients (**Fig. 1f**). Notably, while male patients have been shown to exhibit higher NT₅₀ levels following COVID-19 disease¹⁴, we found here that female patients in fact exhibited a higher level of virus neutralization with a mean NT₅₀ of 299 compared to 154 for males ($p = 0.0116$; **Fig. 1g**). This likely reflects an overrepresentation of older patients and patients with hematological cancers in males in our cohort (**Table 1**).

Given increasing concerns about declining efficacy of SARS-CoV-2 vaccines^{15,16}, we also examined the correlation between NT₅₀ and time post second vaccine dose for these cancer patients. Indeed, we observed a significant, negative correlation ($p = 0.0194$) between time after second dose of mRNA vaccination and NT₅₀ value (**Fig. 1h**). These results confirm the waning immune protection of neutralizing antibodies that are conferred by mRNA vaccination.

In summary, by using a sensitive high-throughput lentivirus-based SARS-CoV-2 neutralization assay⁴, we have examined the neutralizing antibody response of 160 cancer patients and compared, side by side, with that of 46 healthy HCWs. We observed about an approximately 2.4-fold lower neutralizing antibody response in the cancer patients as compared to HCWs, following Pfizer/BioNTech BNT162b2 or Moderna mRNA-1273 vaccination, clearly demonstrating a reduced efficacy of SARS-CoV-2 spike antibody production among cancer patients. This, along with similar observations of some recent complementary studies¹⁷⁻¹⁹, should inform the development of novel immunization strategies for cancer patients. In particular, we find that patients with hematological cancers, such as CLL and NHL, are least likely to respond to mRNA vaccination, with 50-60% of these patients showing no detectable levels of neutralizing antibody against the SARS-CoV-2 spike. Given these findings, booster vaccines may be of particular importance for these groups of cancer patients, with some studies already underway²⁰. Additionally, our

141 finding that B cell depletion or suppression drug treatment significantly reduced the neutralizing antibody
142 response to mRNA vaccines may indicate a need for immunization to occur during disruptions or
143 suspensions in specific treatment protocols.

144 Finally, to better protect immunocompromised populations with increased risk to COVID-19, we must
145 further investigate the duration of vaccine induced immunity as well as the efficacy of booster vaccine doses
146 to determine how to maintain protective immunity in this patient population. Additionally, further study on
147 quality and durability of antigen-specific T and memory B cell responses will provide a more
148 comprehensive understanding of the immune response to SARS-CoV-2 vaccination in these
149 immunocompromised groups. It is also critical to determine the impact of specific treatment protocols on
150 vaccine induced immunity and immunity duration to better inform clinical decisions about the time of
151 vaccination or boosting and the potential need for disruptions in treatment protocols. Results from this work
152 provide critical virological and immunological information for protecting vulnerable populations.

153 154 **Acknowledgments**

155 We thank members of Liu lab for sharing reagents and discussion. We also thank Donna Bucci, Jamie
156 Hamon, Chelsea Bolyard, Kevin Weller, and Taylor Chatlos from the Immune Monitoring and Discovery
157 Platform of the Pelotonia Institute for Immuno-Oncology for assistance in sample collection and discussion.
158 We thank the Clinical Research Center/Center for Clinical Research Management of The Ohio State
159 University Wexner Medical Center and The Ohio State University College of Medicine in Columbus, OH,
160 specifically, Francesca Madiari, Claire Carlin, Dina McGowan, Breona Edwards, and Trina Wemlinger, for
161 collection, processing, and management of samples through the Cardiovascular Medicine JB Biorepository.
162 We thank the NIH AIDS Reagent Program and BEI Resources for supplying important reagents that made
163 this work possible. This work was supported by the Ohio State University Comprehensive Cancer Center
164 and a fund provided by an anonymous private donor to The Ohio State University and NCI U54CA260582
165 to S.-L.L. The content is solely the authors' responsibility and does not necessarily represent the official
166 views of the NIH. S.-L.L. was additionally supported in part by NIH R01 AI150473. Z.L. and P.G.S were

supported by multiple NIH grants. R.J.G. was supported by NIH R01 HL127442-01A1, NCI U54CA260582, and the Cardiovascular Medicine JB Biorepository, and the Robert J. Anthony Fund for Cardiovascular Research. L.S. and E.M.O. were also supported by NCI U54CA260582.

Competing Interests:

The authors report no competing interests.

References:

1. Romano, E., Pascolo, S. & Ott, P. Implications of mRNA-based SARS-CoV-2 vaccination for cancer patients. *Journal for Immunotherapy of Cancer* **9**(2021).
2. Boyarsky, B.J., *et al.* Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients. *Jama* **325**, 1784-1786 (2021).
3. Rabinowich, L., *et al.* Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients. *Journal of Hepatology* (2021).
4. Zeng, C., *et al.* Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers, and convalescent plasma donors. *JCI insight* **5**(2020).
5. Abdul-Jawad, S., *et al.* Acute immune signatures and their legacies in severe acute respiratory syndrome coronavirus-2 infected cancer patients. *Cancer Cell* **39**, 257-275. e256 (2021).
6. Salles, G., *et al.* Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. *Advances in therapy* **34**, 2232-2273 (2017).
7. Mössner, E., *et al.* Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. *Blood, The Journal of the American Society of Hematology* **115**, 4393-4402 (2010).
8. Rada, M., Barlev, N. & Macip, S. BTK: a two-faced effector in cancer and tumour suppression. *Cell death & disease* **9**, 1-3 (2018).
9. Day, C.L., *et al.* PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. *Nature* **443**, 350-354 (2006).
10. Le, D.T., *et al.* PD-1 blockade in tumors with mismatch-repair deficiency. *New England Journal of Medicine* **372**, 2509-2520 (2015).
11. Chamoto, K., Hatae, R. & Honjo, T. Current issues and perspectives in PD-1 blockade cancer immunotherapy. *International journal of clinical oncology* **25**, 790-800 (2020).
12. Zeng, C., *et al.* Neutralization of SARS-CoV-2 Variants of Concern Harboring Q677H. *Mbio* **12**, e02510-02521 (2021).
13. Collier, D.A., *et al.* Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. *Nature* **596**, 417-422 (2021).
14. Shrock, E., *et al.* Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. *Science* **370**(2020).
15. Chemaitelly, H., *et al.* Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. *New England Journal of Medicine* (2021).
16. Keehner, J., *et al.* Resurgence of SARS-CoV-2 infection in a highly vaccinated health system workforce. *New England Journal of Medicine* **385**, 1330-1332 (2021).
17. Monin, L., *et al.* Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. *The Lancet Oncology* (2021).

- 211 18. Shroff, R.T., *et al.* Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults
 212 with solid tumors. *Nature Medicine*, 1-10 (2021).
 213 19. Greenberger, L.M., *et al.* Antibody response to SARS-CoV-2 vaccines in patients with hematologic
 214 malignancies. *Cancer Cell* **39**, 1031-1033 (2021).
 215 20. Greenberger, L.M., *et al.* Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients
 216 with B cell-derived hematologic malignancies. *Cancer cell* (2021).
 217
 218
 219

220
 221 **Table 1. Demographic information of cancer patients**
 222

		Total (n=160)		Male (n=85)		Female (n=75)	
		n	(%)	n	(%)	n	(%)
Age Group (years)	30-44	11	6.9%	1	1.2%	10	13.3%
	45-59	35	21.9%	12	14.1%	23	30.7%
	60-74	96	60.0%	58	68.2%	38	50.7%
	75-85	18	11.3%	14	16.5%	4	5.3%
Race	African American/Black	6	3.8%	2	2.4%	4	5.3%
	Asian Chinese	3	1.9%	2	2.4%	1	1.3%
	Asian Japanese/White	1	0.6%	1	1.2%	0	0.0%
	Other	2	1.3%	1	1.2%	1	1.3%
	White	148	92.5%	79	92.9%	69	92.0%
Vaccine	Moderna	62	38.8%	34	40.0%	28	37.3%
	Pfizer	98	61.3%	51	60.0%	47	62.7%
Cancer Type	CLL	54	33.8%	40	47.1%	14	18.7%
	Lung	29	18.1%	18	21.2%	11	14.7%
	Breast	30	18.8%	0	0.0%	30	40.0%
	CLL/Breast	2	1.3%	0	0.0%	2	2.7%
	Non-Hodgkin's Lymphoma	45	28.1%	27	31.8%	18	24.0%
Anti-B cell therapy	CLL	28	17.5%	23	27.1%	5	6.7%
	Non-Hodgkin's Lymphoma	19	11.9%	11	12.9%	8	10.7%
Anti-PD-1/PD-L1	Lung	26	16.3%	17	20.0%	9	12.0%
	Breast	2	1.3%	0	0.0%	2	2.7%

223 The anti-B cell therapy drugs include Obinutuzumab, Rituximab, Ibrutinib, Zanubrutinib,
 224 Pirtobrutinib and Acalabrutinib.
 225
 226

227 The anti-PD-1/PD-L1 drugs include Nivolumab, Pembrolizumab, Durvalumab and Atezolizumab.
 228

Figure legend

Figure 1. Neutralization of SARS-CoV-2 spike-pseudotyped lentivirus by sera of cancer patients and health care workers. (a) Comparison of 50% neutralization titer (NT_{50}) between cancer patients and health care workers (HCWs). Serially diluted sera were incubated with SARS-CoV-2 spike-pseudotyped lentivirus, followed by infection of 293T-ACE2 cells. The assay was carried out side by side for samples of healthy individuals and cancer patients to ensure valid comparisons. (b) Distribution ranges of NT_{50} among four cancer patient groups. Note that 2 patients who had both CLL and breast cancer were included in each group. (c) Comparison of NT_{50} between anti-B cell therapy and no anti-B cell therapy in cancer patients. Twenty-eight out of the 54 CLL patients and 19 out of the 45 NHL patients received anti-B cell therapy, with drugs including BTK inhibitors and anti-CD20 monoclonal antibodies. (d) Comparison of NT_{50} between Anti-PD1/PD-L1 and no anti-PD1/PD-L1 treatment in lung and breast cancer patients. (e) Comparison of NT_{50} between Moderna and Pfizer vaccinees in health care workers (HCWs) and cancer patients. (f) Correlative analysis between NT_{50} values and ages of cancer patients. (g) Comparison of NT_{50} values between male and female cancer patients. (h) Correlative analysis between NT_{50} values and days of collection after the second dose of vaccination. All correlative analyses were performed using Prism 5 (f and h). In all cases, NT_{50} values indicated at top were calculated by taking the inverse of the 50% inhibitory dilution values obtained from least squares regression non-linear curve modeled with Prism. Statistical significance was determined by a one-tailed unpaired t-test. CLL: Chronic Lymphocytic Leukemia; NHL: Non-Hodgkin's Lymphoma.




Figure 1

Materials and Methods

Vaccinated Cancer Patients and Health Care Workers:

De-identified vaccinated health care worker (HCW)'s serum samples were collected under approved IRB protocols (2020H0228 and 2020H0527). Serum was collected 6 months after the second dose of Pfizer (n=24) and Moderna (n=22) SARS-CoV-2 mRNA vaccine. The ages of the vaccinated groups ranged from 26 years to 61 years (mean age=38.5).

Cancer patient serum samples were collected under an approved IRB protocol (2021C0041). Serum was collected 31~232 days (median 134 days) after the second dose of Pfizer (n=98) and Moderna (n=62) SARS-CoV-2 mRNA vaccines. The age of vaccinated cancer patients ranged from 31 years to 81 years (mean age=66). These cancer patients consisted of 29 lung cancer, 54 chronic lymphocytic leukemia (CLL), 30 breast cancer, 2 CLL and breast cancer, and 45 various non-Hodgkin's lymphomas. Patients were 47% (n=75) female and 53% (n=85) male. Twenty-eight of the 54 CLL patients and 19 of the 45 non-Hodgkin's lymphomas patients received anti-B cell therapy, with drugs including BTK inhibitors and anti-CD20 mAbs during the study period. Twenty-six of the 29 lung cancer patients and 2 of the 30 breast cancer patients received anti-PD-1/PD-L1 therapy.

Cell Culture:

HEK293T cells (ATCC CRL-11268, CVCL_1926) and HEK293T-hACE2 cells (BEI NR-52511) were grown in DMEM (Gibco, 11965-092) supplemented with 10% (vol/vol) fetal bovine serum (Sigma, F1051) and 1% penicillin/streptomycin (HyClone, SV30010). Both cell lines were maintained at 37°C, and 5% CO₂.

Constructs:

The construct used for the production of lentiviral pseudotypes was HIV-1 NL4.3-inGluc¹⁻³, which was originally obtained from David Derse's lab at NIH (National Cancer Institute, Frederick,

Maryland, USA) and Marc Johnson's lab at the University of Missouri (Columbia, Missouri, USA). This construct is based on a Δ Env pNL4.3 HIV-1 vector and contains an anti-sense Gaussia luciferase (Gluc) gene with a sense intron. Gluc is secreted in mammalian cell culture⁴, and the intron and anti-sense orientation of the Gluc gene prevents the production of Gluc in the virus producer cells¹⁻³. pcDNA3.1-SARS-CoV2-S-C9 encoding SARS-CoV-2 full-length spike was obtained from Fang Li's lab at the University of Minnesota (St. Paul, Minnesota, USA).

Virus Production:

Lentiviral pseudotyped virus was produced as previously described¹. Briefly, HEK293T cells were transfected with HIV-1 NL4.3-inGluc and pcDNA3.1-SARS-CoV2-S-C9 constructs in a 2:1 ratio using polyethylimine (PEI). Supernatants were harvested 24 hr, 48 hr, and 72 hr post-transfection and were pooled, aliquoted, and stored at -80°C.

Pseudotype Virus Neutralization Assays:

Pseudotyped virus neutralization assays (VNAs) were performed as previously described¹. Briefly, cancer patients or vaccinee individual serum was 4-fold serially diluted in 96-well plate (Cellstar, 655180), resulting in a final volume of 60 μ L. Subsequently, 100 μ L of pseudotyped virus was added to the plate resulting in a final set of dilutions of 1:40, 1:160, 1:640, 1:2560, 1:10240, and no serum. Virus and serum mixture were incubated for 1 hr at 37°C, and then added to HEK293T-ACE2 cells seeded at 2×10^4 cells/well. Media was changed after 6 hrs post-infection. At 48 hrs and 72 hrs after infection, 20 μ L of media was collected from the cells and transferred to a white, flat-bottomed, polystyrene 96-well plate (Thermo Scientific, 236108). 20 μ L of Gaussia luciferase substrate (0.1 M Tris (MilliporeSigma, #T6066) pH 7.4, 0.3 M sodium ascorbate (Spectrum, S1349), 10 μ M coelenterazine (GoldBio, CZ2.5)) was added to the media and immediately read by a BioTek Cytation5 plate-reader.

Quantification and Statistical Analysis:

Data were analyzed as mean with Standard Error of Mean (SEM), Statistical analyses were performed using GraphPad Prism 5.0 as follows: One-way Analysis of Variance (ANOVA) with Bonferroni's post-tests was used to compute statistical significance (p values) between multiple groups for multiple comparison or t-test was used for two groups for single comparison. The 50% neutralization titer (NT₅₀) was determined using the half-maximal inhibitory concentration values of plasma samples, normalized to control infection, from their serial dilutions. NT₅₀ values were calculated from VNA output using a non-linear regression with least-squares fit in GraphPad Prism5 (GraphPad Software, San Diego, California USA, www.graphpad.com).

Supplementary references:

1. Zeng, C., *et al.* Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers, and convalescent plasma donors. *JCI insight* **5**(2020).
2. Mazurov, D., Ilinskaya, A., Heidecker, G., Lloyd, P. & Derse, D. Quantitative comparison of HTLV-1 and HIV-1 cell-to-cell infection with new replication dependent vectors. *PLoS Pathog* **6**, e1000788 (2010).
3. Yu, J., *et al.* IFITM proteins restrict HIV-1 infection by antagonizing the envelope glycoprotein. *Cell reports* **13**, 145-156 (2015).
4. Goerke, A.R., Loening, A.M., Gambhir, S.S. & Swartz, J.R. Cell-free metabolic engineering promotes high-level production of bioactive *Gaussia princeps* luciferase. *Metabolic engineering* **10**, 187-200 (2008).